ME03328B - Hidrobromidna so n-(4-hloro-2-hidroksi-3-((3s)-3-piperidinilsulfonil)fenil)-n’-(3-fluoro-2-metilfenil)uree - Google Patents

Hidrobromidna so n-(4-hloro-2-hidroksi-3-((3s)-3-piperidinilsulfonil)fenil)-n’-(3-fluoro-2-metilfenil)uree

Info

Publication number
ME03328B
ME03328B MEP-2019-47A MEP201947A ME03328B ME 03328 B ME03328 B ME 03328B ME P201947 A MEP201947 A ME P201947A ME 03328 B ME03328 B ME 03328B
Authority
ME
Montenegro
Prior art keywords
piperidinylsulfonyl
methylphenyl
fluoro
chloro
urea
Prior art date
Application number
MEP-2019-47A
Other languages
German (de)
English (en)
French (fr)
Unknown language (me)
Inventor
Francis Dominic Sanderson
Sarah Mary Vallance
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of ME03328B publication Critical patent/ME03328B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MEP-2019-47A 2013-11-13 2014-11-11 Hidrobromidna so n-(4-hloro-2-hidroksi-3-((3s)-3-piperidinilsulfonil)fenil)-n’-(3-fluoro-2-metilfenil)uree ME03328B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1320021.7A GB201320021D0 (en) 2013-11-13 2013-11-13 Novel Compounds
PCT/EP2014/074222 WO2015071235A1 (en) 2013-11-13 2014-11-11 Hydrobromide salt ofn-(4-chloro-2-hydroxy-3-((3s)-3-piperidinylsulfonyl)phenyl-n'-(3-fluoro-2-methylphenyl)urea
EP14799988.2A EP3068763B1 (en) 2013-11-13 2014-11-11 Hydrobromide salt of n-(4-chloro-2-hydroxy-3-((3s)-3-piperidinylsulfonyl)phenyl)-n'-(3-fluoro-2-methylphenyl)urea

Publications (1)

Publication Number Publication Date
ME03328B true ME03328B (me) 2019-10-20

Family

ID=49818555

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2019-47A ME03328B (me) 2013-11-13 2014-11-11 Hidrobromidna so n-(4-hloro-2-hidroksi-3-((3s)-3-piperidinilsulfonil)fenil)-n’-(3-fluoro-2-metilfenil)uree

Country Status (24)

Country Link
US (3) US9809540B2 (enExample)
EP (1) EP3068763B1 (enExample)
JP (1) JP6401265B2 (enExample)
KR (1) KR20160083950A (enExample)
CN (1) CN105683162A (enExample)
AU (1) AU2014350334B2 (enExample)
BR (1) BR112016010409A8 (enExample)
CA (1) CA2929907A1 (enExample)
CY (1) CY1121581T1 (enExample)
DK (1) DK3068763T3 (enExample)
ES (1) ES2714721T3 (enExample)
GB (1) GB201320021D0 (enExample)
HR (1) HRP20190449T1 (enExample)
HU (1) HUE041873T2 (enExample)
LT (1) LT3068763T (enExample)
ME (1) ME03328B (enExample)
PL (1) PL3068763T3 (enExample)
PT (1) PT3068763T (enExample)
RS (1) RS58382B1 (enExample)
RU (1) RU2685408C1 (enExample)
SI (1) SI3068763T1 (enExample)
SM (1) SMT201900156T1 (enExample)
TR (1) TR201902981T4 (enExample)
WO (1) WO2015071235A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107072976A (zh) * 2014-05-12 2017-08-18 葛兰素史克知识产权第二有限公司 用于治疗传染性疾病的包含Danirixin的药物组合物
BR112018011138A2 (pt) * 2015-11-30 2018-11-21 Glaxosmithkline Intellectual Property (No. formulações para administração intravenosa
WO2018073248A1 (en) 2016-10-17 2018-04-26 Icm (Institut Du Cerveau Et De La Moelle Épinière) Prognosis of demyelinating diseases patients and treatment thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2009992B1 (en) * 2006-04-21 2012-06-27 GlaxoSmithKline LLC Il-8 receptor antagonists

Also Published As

Publication number Publication date
CY1121581T1 (el) 2020-05-29
HUE041873T2 (hu) 2019-05-28
US10604485B2 (en) 2020-03-31
LT3068763T (lt) 2019-03-12
JP6401265B2 (ja) 2018-10-10
EP3068763A1 (en) 2016-09-21
AU2014350334B2 (en) 2017-08-10
JP2016537344A (ja) 2016-12-01
US20190112269A1 (en) 2019-04-18
PL3068763T3 (pl) 2019-05-31
RU2685408C1 (ru) 2019-04-18
ES2714721T3 (es) 2019-05-29
TR201902981T4 (tr) 2019-03-21
US20160264525A1 (en) 2016-09-15
PT3068763T (pt) 2019-03-20
CA2929907A1 (en) 2015-05-21
RS58382B1 (sr) 2019-04-30
CN105683162A (zh) 2016-06-15
AU2014350334A1 (en) 2016-06-02
EP3068763B1 (en) 2018-12-19
SMT201900156T1 (it) 2019-05-10
WO2015071235A1 (en) 2015-05-21
BR112016010409A8 (pt) 2020-04-22
SI3068763T1 (sl) 2019-04-30
RU2016116955A (ru) 2017-12-19
US20180079722A1 (en) 2018-03-22
HRP20190449T1 (hr) 2019-04-19
DK3068763T3 (en) 2019-03-18
KR20160083950A (ko) 2016-07-12
GB201320021D0 (en) 2013-12-25
US9809540B2 (en) 2017-11-07

Similar Documents

Publication Publication Date Title
DK3442947T3 (da) Aminsubstituerede aryl- eller heteroarylforbindelser som ehmt1- og ehmt2-hæmmere
PL3761980T3 (pl) Związki aminokwasowe i sposoby zastosowania
SI3440076T1 (sl) Heterociklični amidi uporabni kot proteinski modulatorji
LT3494115T (lt) N-(fenilsulfonil)benzamido dariniai kaip bcl-2 inhibitoriai
PL3578547T3 (pl) Pochodne sulfonylomocznika i związki pokrewne oraz ich zastosowanie
IL240196A0 (en) Amide compounds, compositions comprising same and uses thereof
IL243200A0 (en) Converted analogs of (e)-n'-(1-phenylethylidene)benzohydrazide as histone demethylase inhibitors
DK3043785T3 (da) Anvendelse af r-ketamin og salt deraf som lægemidler
DK3154950T3 (da) N-(cyanmethyl)-4-(2-(4-morpholinphenylamino)pyrimidin-4-yl)benzamidhydrochloridsalte
EP3728579A4 (en) FUNGAL CELLULASE VARIANTS
EP2962216A4 (en) COMMON USE OF APPLICATION STATES
EP3020090A4 (en) ELECTROLYTIC REGENERATION
EA201591756A1 (ru) Метаболиты n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида
EP2970418A4 (en) STABILIZED EZH2 PEPTIDES
EP2934526A4 (en) ANTIMICROBIAL BISPYRIDINAMINE COMPOSITIONS AND USES
EP2956471A4 (en) IL-1BETA INHIBITOR COMPOSITION AND USE THEREOF
EP2969850A4 (en) INTERMODAL MINI SANDING CONTAINERS AND METHOD FOR USE THEREOF
EP3313865A4 (en) SYNTHETIC PEPTIDE COMPOUNDS AND METHOD OF USE
EP2902391A4 (en) NOVEL AMINE COMPOUND AND USE THEREOF
ME03328B (me) Hidrobromidna so n-(4-hloro-2-hidroksi-3-((3s)-3-piperidinilsulfonil)fenil)-n’-(3-fluoro-2-metilfenil)uree
EP2842937A4 (en) AMIN CONNECTION AND USE THEREOF FOR MEDICAL PURPOSES
EP3651759A4 (en) LITHIUM SALTS OF N-SUBSTITUTED GLYCIN COMPOUNDS AND RELATED USES
IL238529A0 (en) Solid salt form of alpha-6-mpeg6-o-hydroxycodone as opioid agonists and uses thereof
EP3448432A4 (en) TARGETED ADMINISTRATION OF AEROSOLS OF MAGNETIZED ACTIVE AGENTS
EP3345892A4 (en) UREA DERIVATIVE AND USE THEREOF